Interferon-γ Is Increased in Patients with Primary Sjogren's Syndrome and Raynaud's Phenomenon

被引:13
|
作者
Willeke, Peter [1 ]
Schlueter, Bernhard [2 ]
Schotte, Heiko [1 ]
Domschke, Wolfram [1 ]
Gaubitz, Markus [1 ]
Becker, Heidemarie [1 ]
机构
[1] Muenster Univ Hosp, Dept Med B, D-48129 Munster, Germany
[2] Muenster Univ Hosp, Ctr Lab Med, D-48129 Munster, Germany
关键词
Sjogren's syndrome; Raynaud's phenomenon; interferon-gamma; leukopenia; T-cell activation; SYSTEMIC-LUPUS-ERYTHEMATOSUS; PERIPHERAL-BLOOD; T-LYMPHOCYTES; ALPHA; CELLS; DISEASE; ASSOCIATION; INVOLVEMENT; PREVALENCE; EXPRESSION;
D O I
10.1016/j.semarthrit.2008.04.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To determine the prevalence of Raynaud's phenomenon (RP) in patients with primary Sjogren's syndrome (pSS) and to identify clinical and immunological characteristics associated with this manifestation. Since increased interferon-gamma (INF-gamma) has been associated with RP, we also compared the INF-gamma production in pSS patients with or without RP. Methods: RP was diagnosed if pSS patients presented with characteristic sequence of skin color changes of the digits. In uncertain cases noninvasive vascular tests were performed by ultrasound examination. The secretion of INF-gamma by peripheral blood mononuclear cells was assessed by enzyme-linked immunospot analysis. Further, we examined the expression of different lymphocyte activation markers (CD25, CD45RO, CD69) on CD4+ T-cells by flow cytometric analysis. Results: Thirty-six of 108 patients with pSS had RP. In these patients we found a significantly increased number of INF-gamma-secreting peripheral blood mononuclear cells compared with patients without RP or to healthy controls. Further, in patients with RP a significantly increased percentage of CD25-positive T-helper cells was detectable. In addition we found an association of leukopenia, thyroiditis, and lower C3 levels with RP in pSS patients. Conclusions: These results suggest a pathogenic role of INF-gamma in pSS patients with RP. Whether the RP is immune-mediated or whether INF-gamma directly causes vasospasm still remains to be elucidated. (C) 2009 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 39:197-202
引用
收藏
页码:197 / 202
页数:6
相关论文
共 50 条
  • [21] Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis:: a comparative study
    Pamuk, Gulsum Emel
    Turgut, Burhan
    Pamuk, Omer Nuri
    Vural, Ozden
    Demir, Muzaffer
    Cakir, Necati
    BLOOD COAGULATION & FIBRINOLYSIS, 2007, 18 (04) : 297 - 302
  • [22] Comparison of mental and physical health between patients with primary and secondary Raynaud's phenomenon Category: Article
    Fabian, Balazs
    Fabian, Anna Klaudia
    Bugan, Antal
    Csiki, Zoltan
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2019, 116 : 6 - 9
  • [23] Chemokine saliva levels in patients with primary Sjogren's syndrome, associated Sjogren's syndrome, pre-clinical Sjogren's syndrome and systemic autoimmune diseases
    Hernandez-Molina, Gabriela
    Michel-Peregrina, Martha
    Hernandez-Ramirez, Diego F.
    Sanchez-Guerrero, Jorge
    Llorente, Luis
    RHEUMATOLOGY, 2011, 50 (07) : 1288 - 1292
  • [24] Salivary chemokine levels in patients with primary Sjogren's syndrome
    Lee, Yun Jong
    Scofield, Robert H.
    Hyon, Joon Young
    Yun, Pil-Young
    Lee, Hyo-Jung
    Lee, Eun Young
    Lee, Eun Bong
    Song, Yeong Wook
    RHEUMATOLOGY, 2010, 49 (09) : 1747 - 1752
  • [25] Epigenetics in Primary Sjogren's Syndrome
    Bordron, Anne
    Devauchelle-Pensec, Valerie
    Le Dantec, Christelle
    Capdeville, Arthur
    Brooks, Wesley H.
    Renaudineau, Yves
    EPIGENETICS IN ALLERGY AND AUTOIMMUNITY, 2020, 1253 : 285 - 308
  • [26] Subclinical Atherosclerosis in Primary Sjogren's Syndrome: Does Inflammation Matter?
    Bartoloni, Elena
    Alunno, Alessia
    Cafaro, Giacomo
    Valentini, Valentina
    Bistoni, Onelia
    Bonifacio, Angelo Francesco
    Gerli, Roberto
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [27] Interferon Gamma Targeted Therapy: Is It Justified in Primary Sjogren's Syndrome?
    Sebastian, Agata
    Madej, Marta
    Gajdanowicz, Pawel
    Sebastian, Maciej
    Luczak, Anna
    Zemelka-Wiacek, Magdalena
    Jutel, Marek
    Wiland, Piotr
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [28] One year in review 2019: Sjogren's syndrome
    Cafaro, G.
    Croia, C.
    Argyropoulou, O. D.
    Leone, M. C.
    Orlandi, M.
    Finamore, F.
    Cecchettini, A.
    Ferro, F.
    Baldini, C.
    Bartoloni, E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (03) : S3 - S15
  • [29] Molecular Subsetting of Interferon Pathways in Sjogren's Syndrome
    Hall, John C.
    Baer, Alan N.
    Shah, Ami A.
    Criswell, Lindsey A.
    Shiboski, Caroline H.
    Rosen, Antony
    Casciola-Rosen, Livia
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (09) : 2437 - 2446
  • [30] Systemic lupus erythematosus and Sjogren's syndrome induced in a case by interferon-α used for the treatment of hepatitis C
    Onishi, S.
    Nagashima, T.
    Kimura, H.
    Matsuyama, Y.
    Yoshio, T.
    Minota, S.
    LUPUS, 2010, 19 (06) : 753 - 755